https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2756260

Comment; Interesting that use of E-Cigarettes is linked with depression in adolescents. Buproprione would be a great double-duty drug for this group!

Olufunmilayo H. Obisesan, MD, MPH1,2Mohammadhassan Mirbolouk, MD3Albert D. Osei, MD, MPH1,2et alOlusola A. Orimoloye, MD, MPH4S. M. Iftekhar Uddin, MBBS, MSPH1,2Omar Dzaye, MD, PhD5,6Omar El Shahawy, MD, MPH, PhD7,8Mahmoud Al Rifai, MD, MPH9Aruni Bhatnagar, PhD1,10Andrew Stokes, PhD1,11Emelia J. Benjamin, MD, ScM1,11Andrew P. DeFilippis, MD1,10Michael J. Blaha, MD, MPH1,2Author AffiliationsArticle InformationJAMA Netw Open. 2019;2(12):e1916800. doi:10.1001/jamanetworkopen.2019.16800Key Points Español  中文 (Chinese)

Question  What is the association between electronic cigarette (e-cigarette) use and depression?

Findings  In this cross-sectional study of 892 394 participants in the Behavioral Risk Factor Surveillance System from 2016 to 2017, e-cigarette users had higher odds of reporting a history of clinical diagnosis of depression compared with participants who never used e-cigarettes. In addition, increased frequency of e-cigarette use was associated with incrementally higher odds of reporting depression.

Meaning  These findings highlight the need for longitudinal studies to examine the association between e-cigarette use and depression, which may be bidirectional.Abstract

Importance  The prevalence of the use of electronic cigarettes (e-cigarettes) in the United States has grown rapidly since their introduction to the market more than a decade ago. While several studies have demonstrated an association between combustible cigarette smoking and depression, the association between e-cigarette use and depression has not been thoroughly studied.

Objective  To examine the association between e-cigarette use and depression in a nationally representative sample of the adult population in the United States.

Design, Setting, and Participants  Cross-sectional study of the Behavioral Risk Factor Surveillance System database, 2016 to 2017. The Behavioral Risk Factor Surveillance System is the largest national telephone-based survey of randomly sampled adults in the United States. A total of 892 394 participants with information on e-cigarette use and depression were included. Data analysis was conducted in May 2019.

Exposures  Electronic cigarette use status defined by self-report as never, former, or current use.

Main Outcomes and Measures  Self-reported history of a clinical diagnosis of depression.

Results  Of the 892 394 participants (414 326 [29.0%] aged ≥60 years; 502 448 [51.3%] women), there were 28 736 (4.4%) current e-cigarette users, of whom 13 071 (62.1%) were aged between 18 and 39 years. Compared with never e-cigarette users, current e-cigarette users were more likely to be single, male, younger than 40 years, and current combustible cigarette smokers (single, 120 797 [24.3%] vs 10 517 [48.4%]; men, 318 970 [46.6%] vs 14 962 [60.1%]; aged 18-39 years, 129 085 [32.2%] vs 13 071 [62.1%]; current combustible cigarette use, 217 895 [7.9%] vs 8823 [51.8%]). In multivariable adjusted models, former e-cigarette users had 1.60-fold (95% CI, 1.54-1.67) higher odds of reporting a history of clinical diagnosis of depression than never users, whereas current e-cigarette users had 2.10 (95% CI, 1.98-2.23) times higher odds. Additionally, higher odds of reporting depression were observed with increased frequency of use among current e-cigarette users compared with never users (daily use: odds ratio, 2.39; 95% CI, 2.19-2.61; occasional use: odds ratio, 1.96; 95% CI, 1.82-2.10). Similar results were seen in subgroup analyses by sex, race/ethnicity, smoking status, and student status.

Conclusions and Relevance  This study found a significant cross-sectional association between e-cigarette use and depression, which highlights the need for prospective studies analyzing the longitudinal risk of depression with e-cigarette use. If confirmed by other study designs, the potential mental health consequences may have regulatory implications for novel tobacco products.

Dr. Raymond Oenbrink